Despite the apparent achievement of long-term survival with ablative treatment for oligometastatic disease, the level of evidence to support such treatments is weak in many cases, often based on single-arm studies without appropriate controls [ 10].
Interestingly, bevacizumab was approved for recurrent glioblastoma based on single-arm, phase II response data while temozolomide was rejected despite positive survival data, indicating that response remains important in the overall efficacy analysis.
The logged info is based on single emotions.
However, our lives are not based on single issues.
All values are based on single analyses.
We explain these observations within the framework of a size-dependent strength theory based on a single arm source model, dislocation theory, and microstructural analysis by transmission electron microscopy.
In this paper implementation of ANFIS on embedded systems based on single-core and multi-core ARM processors is presented.
However, the results available in literature concerning ERCC1/BRCA1 expression and ERCC1/XPD/XRCC1-3 gene polymorphisms are, overall, not fully consistent, mainly based on retrospective single-arm studies and limited to cisplatin-based chemotherapy.
The benefit of bevacizumab was based on two single-arm phase II studies demonstrating a radiographic response rate of 30 40 % [ 17, 18].
The approval was based on two single-arm, multicenter, open-label trials in which 167 patients were treated (Kim et al. 2008a, b; Piekarz et al. 2009a, 2009b).
